C9orf72 and amyotrophic lateral sclerosis: ,6,7,38 Thus, TI inhibitors may exhibit broad applicability and, as such, offer a compelling alternative to the recently developed antisense oligonucleotide therapy,39 which is tailored exclusively for a small subset of ALS patients with hereditary, monogenic forms of the disease caused, for example, by gain-of-function mutations in SOD1 or C9orf72.40